- 作者：Robert G. Hart ; MD&lowast ; ; robert.hart@phri.ca" class="auth_mail ; Lesly A. Pearce ; MS&dagger ; ; Majid F. Bakheet ; MD&Dagger ; ; Oscar R. Benavente ; MD§ ; ; Robin A. Conwit ; MD鈥?/sup> ; Leslie A. McClure ; PhD¶ ; ; Robert L. Talbert ; PharmD&lowast ; &lowast ; ; David C. Anderson ; MD&dagger ; &dagger ;
- 关键词：Lacunar infarct ; cerebral small-vessel disease ; prognosis ; recurrent stroke
- 刊名：Journal of Stroke and Cerebrovascular Diseases
- 出版年：April, 2014
- 年：2014
- 卷：23
- 期：4
- 页码：618-624
- 全文大小：184 K
ass="h4">Background
Among participants in the Secondary Prevention of Small Subcortical Strokes randomized trial, we sought to identify patients with high versus low rates of recurrent ischemic stroke and to assess effects of aggressive blood pressure control and dual antiplatelet therapy according to risk status.ass="h4">Methods
Multivariable analyses of 3020 participants with recent magnetic resonance imaging-defined lacunar strokes followed for a mean of 3.7聽years with 243 recurrent ischemic strokes.
ass="h4">Results
Prior symptomatic lacunar stroke or transient ischemic attack (TIA) (hazard ratio [HR] 2.2, 95% confidence interval [CI] 1.6, 2.9), diabetes (HR 2.0, 95% CI 1.5, 2.5), black race (HR 1.7, 95% CI 1.3, 2.3), and male sex (HR 1.5, 95% CI 1.1, 1.9) were each independently predictive of recurrent ischemic stroke. Recurrent ischemic stroke occurred at a rate of 4.3% per year (95% CI 3.4, 5.5) in patients with prior symptomatic lacunar stroke or TIA (15% of the cohort), 3.1% per year (95% CI 2.6, 3.9) in those with more than 1 of the other 3 risk factors (27% of the cohort), and 1.3% per year (95% CI 1.0, 1.7) in those with 0-1 risk factors (58% of the cohort). There were no significant interactions between treatment effects and stroke risk status.
ass="h4">Conclusions
In this large, carefully followed cohort of patients with recent lacunar stroke and aggressive blood pressure management, prior symptomatic lacunar ischemia, diabetes, black race, and male sex independently predicted ischemic stroke recurrence. The effects of blood pressure targets and dual antiplatelet therapy were similar across the spectrum of independent risk factors and recurrence risk.